Fate Therapeutics, Inc.
Genomic engineering of pluripotent cells
Last updated:
Abstract:
Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
Status:
Grant
Type:
Utility
Filling date:
9 Apr 2019
Issue date:
27 Jul 2021